// App-Quantinova.ai

5041 : Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.

Researchers

Presenter

  • Nicholas D. James

Principal Investigators

  • Daniel Heinrich

  • Elena Castro

  • Saby George

  • Daniel Y. Song

  • Sabina Dizdarevic

  • Sergio Baldari

  • Markus Essler

  • Igle Jan de Jong

  • Secondo Lastoria

  • Peter G. Hammerer

  • Jeffrey Meltzer

  • Per Sandstrom

  • Frank Verholen

  • Bertrand F. Tombal

  • Joe M. O'Sullivan

  • A. Oliver Sartor

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Department of Medical and Radiation Oncology, Innlandet Hospital Trust, Gjøvik, Norway

  • Virgen de la Victoria Universitary Hospital, Málaga, Spain

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD

  • University Hospitals Sussex NHS Foundation Trust, Clinical Imaging Science Centre, Brighton & Sussex Medical School, University of Sussex and Brighton, Brighton, United Kingdom

  • Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy

  • Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany

  • Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands

  • IRCCS National Cancer Institute, Fondazione Senatore G. Pascale, Naples, Italy

  • Department of Urology, Academic Hospital Braunschweig, Braunschweig, Germany

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Bayer Consumer Care AG, Basel, Switzerland

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast and Northern Ireland Cancer Centre, Belfast, United Kingdom

  • Tulane Cancer Center, Tulane Medical School, New Orleans, LA

Locations

  • United Kingdom

  • Norway

  • Spain

  • United States

  • Italy

  • Germany

  • Netherlands

  • Switzerland

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Alkaline phosphatase

Drug/Treatment

  • Alkaline phosphatase

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved